Gene editor Scribe starts second-half IPO spree with $129M listing

A nine-year-old biotech co-found­ed by CRISPR pi­o­neer Jen­nifer Doud­na is kick­ing off a run of biotech IPOs set for this year’s sec­ond half.

Scribe Ther­a­peu­tics …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.